CARLSBAD, Calif.--(BUSINESS WIRE)--Dec. 14, 2005--SD Pharmaceuticals Inc. (SDP) today announced that it has completed a battery of pre-clinical studies on its novel formulation of Docetaxel. This formulation, designated SDP-014, is a proprietary lyophilized nano-emulsion that does not contain the immunogenic solubilizer polysorbate 80. The battery of seven studies showed equal or superior efficacy in two different cancer models (sarcoma and liver cancer) when compared to the current Taxotere(TM) formulation. SDP-014 also demonstrated no immunogenicity, no detectable hemolysis, no vein irritation and a favorable safety profile when compared to the Taxotere(TM) formulation. The studies were conducted by Dr. Yang Bo in the Dept. of Pharmacology and Toxicology at Zhejiang University in China. The SDP-014 formulation has also passed a 12-month stability test.
